English deutsch Impressum Sitemap Disclaimer   Company Overview Pipeline Collaborations Commercialisation Team Management Team Supervisory Board Medical Advisory Board for RENCAREX® History Facility     Product Development Product Pipeline Philosophy RENCAREX® Overview About RCC Therapeutic Target Phase I & II Phase III ARISER Markets REDECTANE® Overview Functionality Proof−of−concept study Phase III registration trial Market MESUPRON® Overview About Metastasis Therapeutic Target Phase I with WX−UK1 Phase I & II with MESUPRON® WX−554 WX−037 Research Projects Publications For Patients     Investor Relations Strategy Facts Pipeline Key figures Outlook Share Share price Shareholder structure Basic information Financing history Analysts Announcements Press releases Ad hoc announcements Voting Rights Directors' Dealings Financial Reports Presentations Annual General Meeting 2008 2007 2006 Corporate Governance Declaration of compliance Corporate bodies Shareholdings Dates and Events Financial Calendar Conferences Annual Document Annual Document 2007 Annual Document 2006 IR Service     Press Press Releases 2009 Archive Conferences Media Contact Mailing list     Careers     Service Adress & contact template Directions     © 2006 WILEX AG